[go: up one dir, main page]

MX2018008021A - Methods and compositions for the treatment of seizure-related disorders. - Google Patents

Methods and compositions for the treatment of seizure-related disorders.

Info

Publication number
MX2018008021A
MX2018008021A MX2018008021A MX2018008021A MX2018008021A MX 2018008021 A MX2018008021 A MX 2018008021A MX 2018008021 A MX2018008021 A MX 2018008021A MX 2018008021 A MX2018008021 A MX 2018008021A MX 2018008021 A MX2018008021 A MX 2018008021A
Authority
MX
Mexico
Prior art keywords
compositions
methods
seizure
treatment
related disorders
Prior art date
Application number
MX2018008021A
Other languages
Spanish (es)
Inventor
T Went Gregory
Nguyen Jack
Chernoff David
J Fultz Timothy
Ghosh Sangita
Original Assignee
Adamas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharmaceuticals Inc filed Critical Adamas Pharmaceuticals Inc
Publication of MX2018008021A publication Critical patent/MX2018008021A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Las composiciones y métodos se proporcionan para la administración de una composición farmacéutica a un paciente humano. Las composiciones se administran a un paciente humano por vía oral, una vez al día, en una dosis terapéuticamente eficaz. Las composiciones farmacéuticas comprenden un fármaco seleccionado del grupo que consiste de brivaracetam, divalproex, lacosamida, levetiracetam, oxcarbazepina, vigabatrina y sales farmacéuticamente aceptables de cualesquiera de los anteriores y al menos un excipiente, Al menos uno de dicho al menos un excipiente modifica la liberación de dicho fármaco para proporcionar una forma de liberación retrasada, La composición farmacéutica tiene propiedades farmacocinéticas mencionadas en las reivindicaciones.The compositions and methods are provided for the administration of a pharmaceutical composition to a human patient. The compositions are administered to a human patient orally, once a day, in a therapeutically effective dose. The pharmaceutical compositions comprise a drug selected from the group consisting of brivaracetam, divalproex, lacosamide, levetiracetam, oxcarbazepine, vigabatrin and pharmaceutically acceptable salts of any of the foregoing and at least one excipient. At least one of said at least one excipient modifies release of said drug to provide a delayed release form, The pharmaceutical composition has pharmacokinetic properties mentioned in the claims.

MX2018008021A 2015-12-30 2016-12-30 Methods and compositions for the treatment of seizure-related disorders. MX2018008021A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562273187P 2015-12-30 2015-12-30
PCT/US2016/069581 WO2017117569A1 (en) 2015-12-30 2016-12-30 Methods and compositions for the treatment of seizure-related disorders

Publications (1)

Publication Number Publication Date
MX2018008021A true MX2018008021A (en) 2018-11-09

Family

ID=57838557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008021A MX2018008021A (en) 2015-12-30 2016-12-30 Methods and compositions for the treatment of seizure-related disorders.

Country Status (11)

Country Link
US (3) US10973783B2 (en)
EP (1) EP3397253A1 (en)
JP (2) JP6902033B2 (en)
CN (1) CN109069480A (en)
AU (1) AU2016381366A1 (en)
BR (1) BR112018012870A2 (en)
CA (1) CA3008170A1 (en)
IL (1) IL259861A (en)
MA (1) MA43532A (en)
MX (1) MX2018008021A (en)
WO (1) WO2017117569A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CN109069480A (en) 2015-12-30 2018-12-21 阿达玛斯医药公司 For treating the method and composition of illness relevant to epilepsy
CN109255370B (en) * 2018-08-20 2021-07-27 安徽大学 An intelligent spraying method for farmland based on PAUC algorithm
WO2020072773A1 (en) * 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US12042474B2 (en) 2019-06-06 2024-07-23 Shanghai Aucta Pharmaceuticals Co., Ltd. Lacosamide pharmaceutical composition and dosage form thereof
WO2020244615A1 (en) 2019-06-06 2020-12-10 上海奥科达生物医药科技有限公司 Lacosamide pharmaceutical composition and pharmaceutical preparation thereof
CN111407738A (en) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 Brivaracetam controlled-release preparation and preparation method thereof
CN113908153B (en) * 2020-07-09 2024-03-26 上海云晟研新生物科技有限公司 Buvaracetam pharmaceutical composition, preparation method and application thereof
WO2022194198A1 (en) * 2021-03-17 2022-09-22 上海博志研新药物技术有限公司 Lacosamide pharmaceutical composition, preparation method for same, and applications thereof
CN113244197B (en) * 2021-05-24 2023-02-28 天方药业有限公司 Carbamazepine sustained-release capsule and preparation method thereof
CN115343386B (en) * 2022-07-25 2024-09-17 南京海纳医药科技股份有限公司 A method for detecting perampanel in human plasma by HPLC-MS/MS
CN115326960B (en) * 2022-08-11 2024-03-15 复旦大学附属华山医院 Analysis method for simultaneously detecting concentration of 8 antiepileptic drugs and 1 active metabolite in human plasma
EP4559456A1 (en) * 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet of brivaracetam
EP4559457A1 (en) * 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet composition of brivaracetam
US12478587B1 (en) 2025-02-06 2025-11-25 Shanghai Aucta Pharmaceuticals Co., Ltd. Formulation for lacosamide

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (en) 1969-03-10 1970-12-15 Ciba Geigy Ag Process for the production of new azepine derivatives
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
IT1237904B (en) 1989-12-14 1993-06-18 Ubaldo Conte CONTROLLED SPEED RELEASE TABS OF ACTIVE SUBSTANCES
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
KR100221695B1 (en) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 Pharmaceutical Formulation Formulations
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
US6048899A (en) 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ATE216220T1 (en) 1997-12-05 2002-05-15 Alza Corp OSMOTIC DOSAGE FORM WITH TWO LAYERS
US6107492A (en) 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
JP2002532406A (en) 1998-12-17 2002-10-02 アルザ・コーポレーション Conversion of liquid-filled gelatin capsules into controlled-release systems with composite coatings
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
NZ537628A (en) 2002-06-26 2005-12-23 Alza Corp Minimally compliant, volume efficient piston for osmotic drug delivery systems
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
RU2006139930A (en) 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) COMPOSITIONS FOR PROMOTING WEIGHT LOSS
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
TW200616679A (en) 2004-09-30 2006-06-01 Takeda Pharmaceuticals Co Modified-release preparation
JP2006124385A (en) 2004-09-30 2006-05-18 Takeda Chem Ind Ltd Controlled-release pharmaceutical preparation
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US8389578B2 (en) 2004-11-24 2013-03-05 Adamas Pharmaceuticals, Inc Composition and method for treating neurological disease
US20060165745A1 (en) 2005-01-21 2006-07-27 Yiwen Chew Sustained release tablets for treatment of aqueous environment and methods for making the same
AU2005325930B2 (en) 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
EP1731149A1 (en) 2005-06-08 2006-12-13 Ucb S.A. Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
WO2007120485A2 (en) 2006-03-30 2007-10-25 Cinergen, Llc Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
PT2462990E (en) 2006-06-15 2014-04-02 Ucb Pharma Gmbh Pharmaceutical composition comprising lacosamide and levetiracetam with synergistic anticonvulsant effect
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (en) 2006-06-15 2014-03-12 优时比制药有限公司 Peptide compounds for the treatment of refractory status epilepticus
ES2365574T3 (en) 2007-01-11 2011-10-07 Xenoport, Inc. ORAL DOSAGE FORMS FOR CONTINUOUS RELEASE OF A R-BACLOFEN PROPHARM AND TREATMENT PROCEDURES.
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
MX2010009222A (en) 2008-03-03 2010-09-28 Ucb Pharma Sa Pharmaceutical solutions, process of preparation and therapeutic uses.
US20090298947A1 (en) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Polymorphic and amorphous forms of lacosamide and amorphous compositions
WO2009144286A1 (en) 2008-05-30 2009-12-03 Ucb Pharma, S.A. Pharmaceutical compositions comprising brivaracetam
MX2011000636A (en) 2008-07-18 2011-08-03 Valeant Pharmaceuticals Int Modified release formulation and methods of use.
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
AU2009303834B2 (en) 2008-10-16 2016-08-11 The Johns Hopkins University Methods and compositions for improving cognitive function
CN104083341A (en) 2008-11-18 2014-10-08 Ucb医药有限公司 Prolonged Release Formulations Comprising an 2-Oxo-1-Pyrrolidine Derivate
BRPI0921313A2 (en) 2008-11-18 2015-12-29 Ucb Pharma Sa pharmaceutical composition
DE102008059155A1 (en) 2008-11-27 2010-06-02 Ratiopharm Gmbh Dry processing and new forms of lacosamide
GB2467312B (en) * 2009-01-28 2013-06-26 Mark Labudek Design Ltd Titanium alloy, a method of producing the alloy and an article made of the alloy
PL2391351T3 (en) 2009-01-29 2015-02-27 Ucb Pharma Sa Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
WO2010094535A1 (en) 2009-01-29 2010-08-26 Ucb Pharma, S.A. Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
EP2393483B1 (en) * 2009-02-09 2017-06-28 UCB Biopharma SPRL Pharmaceutical compositions comprising brivaracetam
CN102596897A (en) 2009-08-06 2012-07-18 麦迪凯姆股份公司 Solid forms of an N-(phenylmethyl)propanamide derivative and processes of preparation
MX350056B (en) 2009-11-03 2017-08-25 Lupin Ltd Modified release formulation of lacosamide.
BR112012013487A2 (en) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc AMANTADINE COMPOSITIONS AND METHODS OF USE
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
EP2563339A1 (en) 2010-04-29 2013-03-06 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
EP2646001A2 (en) 2010-12-02 2013-10-09 UCB Pharma GmbH Formulation of lacosamide
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
AU2011376333A1 (en) 2011-09-07 2014-03-13 Novartis Ag Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
KR101732731B1 (en) 2013-04-02 2017-05-08 주식회사 바이오파마티스 Pharmaceutical compositions for easy control of releasing pattern of lacosamide or pharmaceutically acceptable salts thereof
PL2801352T3 (en) 2013-05-08 2017-12-29 Sanovel Ilac Sanayi Ve Ticaret A.S. Orally disintegrating formulations of Lacosamid
WO2014180912A1 (en) 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Modified release formulations of lacosamide
WO2014180895A1 (en) 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations of lacosamide
US20170035733A1 (en) 2013-11-29 2017-02-09 Ucb Pharma Gmbh Pharmaceutical composition comprising lacosamide and levetiracetam
CN109069480A (en) 2015-12-30 2018-12-21 阿达玛斯医药公司 For treating the method and composition of illness relevant to epilepsy

Also Published As

Publication number Publication date
US10973783B2 (en) 2021-04-13
US10987324B2 (en) 2021-04-27
IL259861A (en) 2018-07-31
US20180161282A1 (en) 2018-06-14
WO2017117569A1 (en) 2017-07-06
US20170189342A1 (en) 2017-07-06
EP3397253A1 (en) 2018-11-07
JP2019500353A (en) 2019-01-10
US20220062204A1 (en) 2022-03-03
CA3008170A1 (en) 2017-07-06
CN109069480A (en) 2018-12-21
JP6902033B2 (en) 2021-07-14
MA43532A (en) 2018-11-07
BR112018012870A2 (en) 2018-12-04
AU2016381366A1 (en) 2018-06-28
JP2021095418A (en) 2021-06-24

Similar Documents

Publication Publication Date Title
MX2018008021A (en) Methods and compositions for the treatment of seizure-related disorders.
UY35624A (en) USE OF HIGH DOSE PRIDOPIDINE TO TREAT HUNTINGTON'S DISEASE
CY1119886T1 (en) METHOD FOR MANUFACTURING OF A PHARMACEUTICAL COMPOSITION IN FORM OF PROLONGED RELEASE TABLET CONTAINING pirfenidone and uses thereof regression CHRONIC RENAL DEFICIENCY, KAPSIKIS SYSPASIS udder of hepatic INOSIS IN HUMANS
FI3435996T3 (en) ELAFIBRANOR FOR USE IN THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
MX2016010179A (en) COMPOSITIONS OF DONEPEZILO AND METHODS TO TREAT ALZHEIMER'S DISEASE.
BR112015020389A8 (en) carbazole compounds useful as bromodomain inhibitors, their use as well as pharmaceutical composition and product comprising them
JP2015038135A5 (en)
JP2012193216A5 (en)
CL2018001199A1 (en) Therapeutic compositions for the treatment of human immunodeficiency virus
PE20150161A1 (en) USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
JP2017506624A5 (en)
MA37455A1 (en) Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
BRPI0925315B8 (en) pharmaceutical composition of fixed dosage, oral, solid, stable in the form of a monolayer tablet, process for its preparation and use of irbesartan and amlodipine besylate
CR20180184A (en) HETEROARILO COMPOUNDS AND ITS USE AS THERAPEUTIC DRUGS
MX2020004107A (en) DELAYED RELEASE DEFERIPRONE TABLETS AND METHODS OF USE THEREOF.
CO2022005926A2 (en) Complement factor d inhibitors for oral administration
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
RU2018146504A (en) Treatment of intrahepatic cholestatic diseases
WO2014119985A3 (en) Pharmaceutical composition comprising a selective phosphodiesterase enzyme inhibitor in oral gel form
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
UY31790A (en) USE OF DRONEDARONA TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRITMIA AND THAT HAVE AN INCREASE OF THE CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONA
HRP20161796T1 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patient which have been subjected to gastric bypass-surgery
AR088845A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 7- (1H-IMIDAZOL-4-ILMETIL) -5,6,7,8-TETRAHYDRO-QUINOLINE FOR THE TREATMENT OF SKIN DISEASES AND AFFECTIONS
CO2018009543A2 (en) Extended release pharmaceutical composition comprising cysteamine or salt thereof
BR112018008835A2 (en) oral pharmaceutical composition, oral pulsatile release pharmaceutical composition, method for treating a disease condition requiring dimethyl fumarate therapy and method for treating multiple sclerosis